BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 137.69% | -8.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 137.69% | -8.34% | |||
| Cost of Revenue | 640.75% | -8.36% | |||
| Gross Profit | 37.35% | -8.34% | |||
| SG&A Expenses | 0.32% | -13.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.42% | -7.49% | |||
| Operating Income | 41.15% | 6.69% | |||
| Income Before Tax | 45.26% | -1,302.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.26% | -1,302.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.26% | -1,302.89% | |||
| EBIT | 41.15% | 6.69% | |||
| EBITDA | 57.55% | 14.16% | |||
| EPS Basic | 51.02% | -1,325.00% | |||
| Normalized Basic EPS | 70.00% | -1,100.00% | |||
| EPS Diluted | 51.02% | -1,325.00% | |||
| Normalized Diluted EPS | 70.00% | -1,100.00% | |||
| Average Basic Shares Outstanding | 9.05% | 0.16% | |||
| Average Diluted Shares Outstanding | 9.05% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||